ALZAMEND NEURO, INC. Temporary Equity, Par Value
ALZAMEND NEURO, INC. (ALZN) had Temporary Equity, Par Value of $477.74 thousand as of 2024-01-31, per its 10-Q filed 2024-03-25.
Discontinued › Balance Sheet › Equity
us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital · last filed 2024-03-25
- 2024-01-31: Temporary Equity, Par Value $477.74K.
| Period end | Temporary Equity, Par Value |
|---|---|
| 2024-01-31 | $477.74K 10-Q · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |